CLINICAL TRIALS PROFILE FOR CTP-543

Clinical Trials for CTP-543

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02777008 ↗	Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects	Completed	Concert Pharmaceuticals	Phase 1	Single- and multiple-ascending dose study of CTP-543 in healthy volunteers.
NCT02960945 ↗	Open-Label Crossover Study Comparing CTP-543 to Jakafi®	Completed	Concert Pharmaceuticals	Phase 1	This study will assess the metabolite and pharmacokinetic (PK) profile of a single dose of CTP-543 compared to a single dose of Jakafi® in healthy volunteers.
NCT03137381 ↗	Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata	Completed	Concert Pharmaceuticals	Phase 2	This study will evaluate the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.
NCT03811912 ↗	Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata	Completed	Concert Pharmaceuticals	Phase 2	A randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata
NCT03880136 ↗	Food Effect Study of CTP-543 in Healthy Volunteers	Completed	Concert Pharmaceuticals	Phase 1	Two period crossover study to assess the bioavailability of CTP-543 under fed and fasted conditions.
NCT03898479 ↗	Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata	Recruiting	Concert Pharmaceuticals	Phase 2/Phase 3	The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
NCT03941548 ↗	Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata	Completed	Concert Pharmaceuticals	Phase 2	A randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata

Clinical Trial Conditions for CTP-543

Condition Name

Condition Name
Intervention	Trials
Alopecia Areata	8
Healthy Volunteers	5
Health Volunteers	3
Healthy	3

Condition MeSH

Condition MeSH
Intervention	Trials
Alopecia Areata	8
Alopecia	8
Renal Insufficiency	1
Liver Diseases	1

Clinical Trial Locations for CTP-543

Trials by Country

Trials by Country
Location	Trials
United States	123
Canada	16
Poland	8
France	6
Germany	6

Trials by US State

Trials by US State
Location	Trials
Florida	15
Texas	6
Oregon	6
California	6
Massachusetts	5

Clinical Trial Progress for CTP-543

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	12
Recruiting	7
Active, not recruiting	2

Clinical Trial Sponsors for CTP-543

Sponsor Name

Sponsor Name
Sponsor	Trials
Concert Pharmaceuticals	21
Celerion	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	23